Investing.com - Financial Markets Worldwide
💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

EU drugs agency: swine flu vaccine data "promising"

Published 09/10/2009, 08:05 AM
Updated 09/10/2009, 08:09 AM
GSK
-

LONDON, Sept 10 (Reuters) - Early clinical trial results suggest that swine flu vaccines now being rushed through development produce a strong immune response, suggesting they should work well, the head of Europe's drugs watchdog said on Thursday.

"It seems to be quite promising," Thomas Lonngren, executive director of the European Medicines Agency (EMEA), told reporters.

"The immune respomnse to all these vaccines is a very high response, whatever type of vaccine it is, whether it is adjuvanted or non-adjuvanted," he added.

Adjuvants are substances added to vaccines to boost their effectiveness.

The EMEA's expert committee on new medicines will consider the first three H1N1 swine flu vaccines from GlaxoSmithKline, Novartis and Baxter at its next meeting during the week commencing Sept. 21.

If all goes well, the first swine flu vaccines could be licensed by the European Commission early in October, Lonngren said. (Reporting by Ben Hirschler and Kate Kelland)

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.